IpamorelinvsTesamorelin

Ipamorelin is a pentapeptide growth hormone secretagogue that binds selectively to the growth hormone secretagogue receptor type 1a (GHS-R1a), the same receptor that endogenous ghrelin activates. However, unlike ghrelin and other GHRPs such as GHRP-6 and Hexarelin, ipamorelin demonstrates remarkable selectivity — it stimulates robust GH release while causing minimal elevation of cortisol, prolactin, and ACTH at therapeutic doses.

At the molecular level, ipamorelin binding to GHS-R1a on pituitary somatotrophs activates a Gq/11-coupled signaling cascade that stimulates phospholipase C (PLC), generating inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 triggers calcium release from intracellular stores, while DAG activates protein kinase C. The resulting rise in intracellular calcium triggers GH vesicle exocytosis. This mechanism is distinct from and synergistic with the cAMP pathway activated by GHRH, which is why combining ipamorelin with a GHRH analogue like CJC-1295 produces amplified GH pulses.

The selectivity of ipamorelin is attributed to its specific binding conformation at the GHS-R1a receptor, which activates the GH release pathway without engaging the broader hypothalamic-pituitary-adrenal axis. It does not significantly activate appetite centers in the hypothalamus at standard doses, nor does it stimulate ACTH release from corticotrophs. This clean side-effect profile has made it the most widely prescribed growth hormone secretagogue in anti-aging and regenerative medicine, often considered the safest starting point for patients new to GH-optimizing peptide therapy.

Tesamorelin is a synthetic GHRH analogue consisting of all 44 amino acids of human GHRH with a trans-3-hexenoic acid group attached to the tyrosine at position 1. This lipophilic modification enhances receptor binding affinity and provides modest resistance to dipeptidyl peptidase-IV (DPP-IV) cleavage, improving its pharmacokinetic profile compared to native GHRH.

Like other GHRH analogues, tesamorelin activates the GHRH receptor on pituitary somatotrophs via the Gs/cAMP/PKA pathway, stimulating endogenous GH synthesis and pulsatile secretion. The resulting increase in circulating GH and IGF-1 produces its primary therapeutic effect: targeted reduction of visceral adipose tissue (VAT). GH-mediated lipolysis is particularly active in visceral fat depots because these adipocytes have the highest density of GH receptors and are most responsive to GH-stimulated hormone-sensitive lipase activation.

The specificity of tesamorelin's effect on visceral rather than subcutaneous fat has been well-documented in clinical trials. Visceral adipose tissue is metabolically distinct — it drains directly into the portal circulation and contributes disproportionately to hepatic insulin resistance, inflammatory cytokine production, and cardiovascular risk. By selectively reducing this depot, tesamorelin improves the cardiometabolic profile beyond what would be expected from total fat loss alone. Clinical trials also showed improvements in hepatic steatosis (fatty liver) markers, triglyceride levels, and trunk fat distribution. It remains the only GHRH analogue with active FDA approval, specifically for HIV-associated lipodystrophy, where visceral fat accumulation is a common and distressing side effect of antiretroviral therapy.